循環器医と総合医が協働して執筆した画期的な心不全診療の書籍です！

書籍には含めなかった文献一覧のほか、退院診療情報提供書・退院後初診時チェックリストのテンプレートファイルを提供しています。

参考文献

Part 1　心不全の診断／進展ステージ (抜粋)

[1]心不全の診断

  1. Okura Y, et al. Impending epidemic: future projection of heart failure in Japan to the year 2055. Circ J. 2008; 72: 489-491.
  2. 日本循環器学会/日本心不全学会合同ガイドライン. 2025年改訂版 心不全診療ガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2025/03/JCS2025_Kato.pdf（2025年5月9日閲覧）
  3. 一般社団法人日本心不全学会. 血中BNPやNT-proBNPを用いた心不全診療に関するステートメント2023年改訂版. https://www.jhfs.or.jp/statement-guideline/files/statement20231017.pdf（2025年5月9日閲覧）
  4. Tsuchihashi M, et al. Clinical characteristics and prognosis of hospitalized patients with congestive heart failure - a study in Fukuoka, Japan. Circ J. 2000; 64: 953-959.

[2]心不全治療薬の使い方・考え方

CONSENSUS
CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987; 316: 1429-1435.
SOLVD
SOLVD Investigators; Yusuf S, et al. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991; 325: 293-302.
CHARM
  • Cohn JN, et al. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001; 345: 1667-1675.
  • Granger CB, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003; 362: 772-776.
  • McMurray JJV, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet. 2003; 362: 767-771.
US Carvedilol
Packer M, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106: 2194-2199.
COPERNICUS
Packer M, et al. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation. 2002; 106: 2194-2199.
CIBIS-2
The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999; 353: 9-13.
RALES
Pitt B, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709-717.
EMPHASIS-HF
Zannad F, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011; 364: 11-21.
DAPA-HF
McMurray JJV, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. N Engl J Med. 2019; 381: 1995-2008.
EMPEROR-Reduced
Packer M, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure. N Engl J Med. 2020; 383: 1413-1424.
EMPEROR-Preserved
Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385: 1451-1461.
DELIVER
Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387: 1089-1098.
FINEARTS-HF
Solomon SD, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024; 391: 1475-1485.
EMPULSE
Voors AA, et al. The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial. Nat Med. 2022; 28: 568-574.
DICTATE-AHF
Cox ZL, et al. Efficacy and Safety of Dapagliflozin in Patients With Acute Heart Failure. J Am Coll Cardiol. 2024; 83: 1295-1306.

[3]心不全の非薬物療法～不整脈編～

  1. Marrouche NF, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018; 378: 417-427.
  2. Prabhu S, et al. Catheter Ablation Versus Medical Rate Control in Atrial Fibrillation and Systolic Dysfunction: The CAMERA-MRI Study. J Am Coll Cardiol. 2017; 70: 1949-1961.
  3. 日本循環器学会/日本不整脈心電学会合同ガイドライン．2024年JCS/JHRSガイドラインフォーカスアップデート版　不整脈治療． https://www.j-circ.or.jp/cms/wp-content/uploads/2024/03/JCS2024_Iwasaki.pdf（2025年9月17日閲覧）
  4. Mahalleh M, et al. A risk stratification model for predicting incident heart failure in patients with recently diagnosed atrial fibrillation. Heart Fail Rev. 2025; 30: 1-5.
  5. Kirchhof P, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020; 383: 1305-1316.
  6. Rillig A, et al. Clinical Outcomes After Ablation Index-Guided High-Power Short-Duration Ablation of Atrial Fibrillation. Circulation. 2022; 146: 836-847.
  7. Lee SR, et al. Temporal Trends and Factors Associated With Increased Use of Oral Anticoagulants and Declining Use of Aspirin in Patients With Atrial Fibrillation. JACC Clin Electrophysiol. 2023; 9: 1121-1133.
  8. Andrade JG, et al. Ablation of Persistent Atrial Fibrillation in Patients with Heart Failure. N Engl J Med. 2023; 388: 105-116.
  9. Boriani G, et al. Contemporary stroke prevention strategies in 11 096 European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. Europace. 2018; 20: 747-757.
  10. Wazni OM, et al. Cryoballoon Ablation as Initial Therapy for Atrial Fibrillation. N Engl J Med. 2021; 384: 316-324.
  11. Andrade JG, et al. Ablation of Persistent Atrial Fibrillation in Patients with Heart Failure. N Engl J Med. 2023; 388: 105-116.
  12. Kuniss M, et al. Cryoballoon vs. radiofrequency ablation of paroxysmal atrial fibrillation: durability of pulmonary vein isolation and effect on atrial fibrillation burden: the prospective multicentre FROZEN AF study. Europace. 2021; 23: 1033-1041.
  13. Andrade JG, et al. Cryoballoon Ablation as Initial Treatment for Atrial Fibrillation: JACC State-of-the-Art Review. J Am Coll Cardiol. 2021; 78: 914-930.
  14. Cresti A, et al. Prevalence of extra-appendage thrombosis in non-valvular atrial fibrillation and atrial flutter in patients undergoing cardioversion: a large transoesophageal echo study. EuroIntervention. 2019; 15: e225-e230.
  15. 日本循環器学会. 左心耳閉鎖システムに関する適正使用指針．https://www.j-circ.or.jp/cms/wp-content/uploads/2024/12/WMusage-guidelines20241206.pdf（2025年5月9日閲覧）
  16. Holmes Jr DR, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009; 374: 534-542.
  17. Holmes Jr DR, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. J Am Coll Cardiol. 2014; 64: 1-12.
  18. Reddy VY, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. J Am Coll Cardiol. 2017; 70: 2964-2975.
  19. Osmancik P, et al. Left Atrial Appendage Closure vs Novel Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. J Am Coll Cardiol. 2022; 79: 1-14.
  20. Kar S, et al. Prospective, Multicenter, Randomized, Controlled Trial of Left Atrial Appendage Occlusion Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: WATCHMAN FLX Pivotal Trial. Circulation. 2021; 143: 1754-1762.
  21. Reinhardt SW, et al. Anticoagulation Versus Left Atrial Appendage Occlusion With WATCHMAN for Atrial Fibrillation: A Comparison of Outcomes. J Am Coll Cardiol. 2024; 84: 889-900.
  22. Lima NA, et al. Benefits of a complete left atrial appendage closure with the Watchman FLX device. Heart Rhythm. 2024; 21: 1278-1285.
  23. Turagam MK, et al. Left Atrial Appendage Closure Versus Oral Anticoagulation in Patients With Atrial Fibrillation and End-Stage Renal Disease: A Cost-Effectiveness Analysis. JACC Clin Electrophysiol. 2024; 10: 270-283.
  24. Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43: 3997-4126.
  25. Ling Z, et al. Effects of radiofrequency catheter ablation of ventricular tachycardia on the left ventricular ejection fraction in patients with implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol. 2014; 7: 237-243.
  26. Bogun F, et al. Radiofrequency ablation of frequent, idiopathic premature ventricular complexes: comparison with a control group without intervention. Heart Rhythm. 2007; 4: 863-867.
  27. de Diego C, et al. Effects of catheter ablation of premature ventricular complexes on left ventricular function in patients with heart failure. Heart Rhythm. 2018; 15: 395-402.
  28. Zeppenfeld K, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022; 43: 3997-4126.
  29. Lakkireddy D, et al. Effect of catheter ablation and surgical intervention on procedural outcomes and left ventricular function in patients with cardiac myxoma. J Am Coll Cardiol. 2012; 60: 1351.
  30. Hong JA, et al. Effect of catheter ablation of ventricular premature complex on left ventricular function in patients with left ventricular dysfunction. ESC Heart Fail. 2022; 9: 283-292.
  31. Huang HT, et al. Impact of catheter ablation on clinical outcomes in patients with ventricular premature complexes and left ventricular dysfunction. ESC Heart Fail. 2022; 9: 3825-3835.
  32. Kies P, et al. Impaired cardiac sympathetic innervation in symptomatic patients with long QT syndrome. Eur J Nucl Med Mol Imaging. 2011; 38: 1899-1907.
  33. Arias FGR, et al. Left Ventricular Ejection Fraction Recovery in Patients With Nonischemic Dilated Cardiomyopathy and an Implantable Cardioverter-defibrillator. Rev Esp Cardiol (Engl Ed). 2023; 76: 238-244.
  34. Savarese G, et al. Utilization of Implantable Cardioverter-Defibrillators in Patients With Heart Failure. JACC Heart Fail. 2019; 7: 306-317.
  35. Leyva F, et al. 2022 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Europace. 2023; 25: euad059.
  36. Wang NC, et al. ICD discrimination between ventricular and supraventricular arrhythmias: a narrative review of electrogram-based algorithms. Pacing Clin Electrophysiol. 2018; 41: 143-154.
  37. 日本循環器学会 /日本不整脈心電学会合同ガイドライン．不整脈非薬物治療ガイドライン（2018 年改訂版）． https://www.j-circ.or.jp/cms/wp-content/uploads/2018/07/JCS2018_kurita_nogami.pdf（2025年9月17日閲覧）
  38. Mullens W, et al. Importance of adjunctive heart failure optimization immediately after implantation to improve long-term outcomes with cardiac resynchronization therapy. Am J Cardiol. 2011; 108: 409-415.
  39. Yagishita D, et al. Long-term outcome of left bundle-branch pacing in patients with heart failure with left bundle-branch block. Heart Rhythm. 2019; 16: 395-402.
  40. Wang Z, et al. The Role of His-Purkinje Conduction System in Cardiac Resynchronization Therapy. Front Cardiovasc Med. 2021; 8: 700424.
  41. Waddingham PH, et al. Permanent His bundle pacing: an international multicentre experience. Europace. 2023; 25: 536-545.
  42. Wilkoff BL, et al. Left bundle branch area pacing versus right ventricular pacing for conduction system disease (LBBAP): a randomized trial. Lancet. 2023; 402: 1147-1157.
  43. Rickard J, et al. Predictors of response to cardiac resynchronization therapy: A systematic review. Int J Cardiol. 2016; 225: 345-352.
  44. Brignole M, et al. ESC Guidelines on cardiac pacing and cardiac resynchronization therapy. Eur Heart J. 2021; 42: 4731-4739.
  45. Pappone C, et al. Atrioventricular junction ablation combined with either right ventricular pacing or cardiac resynchronization therapy for atrial fibrillation: the APAF-CRT mortality trial. Heart Rhythm. 2014; 11: 394-401.
  46. Leonardo C, et al. Left bundle branch area pacing in patients with heart failure and left bundle branch block: results of 1-year follow-up. Europace. 2024; 26: euae259.
  47. Niazi I, et al. His Bundle Pacing: A New Standard for Bradycardia Devices? J Am Coll Cardiol EP. 2017; 3: 1510-1518.
  48. Verma N, et al. Non-Fluoroscopic Cardiac Resynchronization Therapy Implantation Using Electroanatomic Mapping System. Circ Arrhythm Electrophysiol. 2020; 13: e008680.
  49. Chen X, et al. Permanent His Bundle Pacing in Cardiovascular Implantable Electronic Device Recipients: A Systematic Review and Meta-Analysis. Circ Arrhythm Electrophysiol. 2023; 16: e011761.
  50. Padala SK, et al. Challenges and Limitations of His Bundle Pacing. JACC Clin Electrophysiol. 2020; 6: 1773-1782.
  51. De Pooter J, et al. Left Bundle Branch Area Pacing Versus His Bundle Pacing: A Multicenter Study. JACC Clin Electrophysiol. 2025; 11: 158-170.
  52. Steinwender C, et al. Leadless Cardiac Pacemaker Implantation After Lead Extraction in Patients With Severe Device Infection. J Am Coll Cardiol EP. 2020; 6: 94-106.
  53. Neuzil P, et al. Long-term outcomes of leadless cardiac pacing: A systematic review and meta-analysis. J Am Coll Cardiol. 2024; S0735-1097: 10292-6.
  54. Roberts PR, et al. Leadless Pacing: State-of-the-Art 2022. Arrhythm Electrophysiol Rev. 2022; 11: e19.

[4]心不全の非薬物療法　ストラクチャー（弁膜症治療＋虚血）

  1. OʼNeill WW, et al. The current use of Impella 2.5 in acute myocardial infarction complicated by cardiogenic shock: results from the USpella Registry. J Interv Cardiol 2014; 27: 1- 11.
  2. Basir MB, et al. Effect of Early Initiation of Mechanical Circulatory Support on Survival in Cardiogenic Shock. Am J Cardiol. 2017; 119: 845-851.
  3. Maron DJ, et al. Initial Invasive or Conservative Strategy for Stable Coronary Disease. N Engl J Med. 2020; 382: 1395-1407.
  4. Perera D, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022; 387: 1351-1360.
  5. Généreux P, et al. Transcatheter Aortic-Valve Replacement for Asymptomatic Severe Aortic Stenosis. N Engl J Med. 2025; 392: 217-227.
  6. Mack MJ, et al. Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients. N Engl J Med. 2019; 380: 1695-1705.
  7. Jubran A, et al. Lifetime Management of Patients With Severe Aortic Stenosis in the Era of Transcatheter Aortic Valve Replacement. Can J Cardiol. 2024; 40: 210-217.
  8. Kirker E, et al. Transcarotid Versus Subclavian/Axillary Access for Transcatheter Aortic Valve Replacement With SAPIEN 3. Ann Thorac Surg. 2020; 110: 1892-1897.
  9. Thyregod HGH, et al. Transcatheter or surgical aortic valve implantation: 10-year outcomes of the NOTION trial. Eur Heart J. 2024; 45: 1116-1124.
  10. Mieghem NMV, et al. Transcatheter Aortic Valve Replacement in Patients With Systolic Heart Failure and Moderate Aortic Stenosis: TAVR UNLOAD. J Am Coll Cardiol. 2025; 85: 878-890.
  11. Feldman T, et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med. 2011; 364: 1395-1406.
  12. Bardeleben RSV, et al. 1-Year Outcomes With Fourth-Generation Mitral Valve Transcatheter Edge-to-Edge Repair From the EXPAND G4 Study. JACC Cardiovasc Interv. 2023; 16: 2600-2610.
  13. Zahr F, et al. One-Year Outcomes From the CLASP IID Randomized Trial for Degenerative Mitral Regurgitation. JACC Cardiovasc Interv. 2023; S1936-8798: 01358-4.
  14. Marcoff L, et al. Echocardiographic Outcomes With Transcatheter Edge-to-Edge Repair for Degenerative Mitral Regurgitation in Prohibitive Surgical Risk Patients. JACC Cardiovasc Imaging. 2024; 17: 471-485.
  15. Obadia JF, et al. Percutaneous Repair or Medical Treatment for Secondary Mitral Regurgitation. N Engl J Med. 2018; 379: 2297-2306.
  16. Stone GW, et al. Transcatheter Mitral-Valve Repair in Patients with Heart Failure. N Engl J Med. 2018; 379: 2307-2318.
  17. Anker SD, et al. Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation. N Engl J Med. 2024; 391: 1799-1809.
  18. Baldus S, et al. Transcatheter Repair versus Mitral-Valve Surgery for Secondary Mitral Regurgitation. N Engl J Med. 2024; 391: 1787-1798.

[6]栄養指導・生活習慣変容・セルフケア

  1. Tsuchihashi M et al. Clinical characteristics and prognosis of hospitalized patients with congestive heart failure--a study in Fukuoka, Japan. Jpn Circ J. 2000; 64: 953-959.
  2. 日本循環器学会/日本心不全学会合同ガイドライン．2025年改訂版　心不全診療ガイドライン． https://www.j-circ.or.jp/cms/wp-content/uploads/2025/03/JCS2025_Kato.pdf（2025年9月17日閲覧）
  3. 厚生労働省．令和４年国民健康・栄養調査結果の概要. https://www.mhlw.go.jp/content/10900000/001296359.pdf（2025年9月17日閲覧）
  4. Anderson CAM, et al. Dietary sources of sodium in China, Japan, the United Kingdom, and the United States, women and men aged 40 to 59 years: the INTERMAP study. J Am Diet Assoc. 2010; 110: 736–745.
  5. He FJ, et al. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open. 2014; 4: e004549.
  6. Ezekowitz JA, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (SODIUM-HF): an international, open-label, randomised, controlled trial. Lancet. 2022; 399: 1391-1400.
  7. 日本心不全学会ガイドライン委員会（編）．心不全患者における栄養評価・管理に関するステートメント．2018． https://www.jhfs.or.jp/statement-guideline/files/statement20181012.pdf（2025年9月17日閲覧）
  8. Ikoma T, et al. The Importance of Objective Nutritional Indexes in Heart Failure Patients. J Am Coll Cardiol. 2021; 78: 855-856.

[7] ポリファーマシー

  1. Masnoon N, et al. What is polypharmacy? A systematic review of definitions. BMC Geriatr 2017; 17: 230.
  2. 厚生労働省．令和３年社会医療診療行為別統計の概況． https://www.mhlw.go.jp/toukei/saikin/hw/sinryo/tyosa21/（2025年9月17日閲覧）
  3. Unlu O, et al. Polypharmacy in Older Adults Hospitalized for Heart Failure. Circ Heart Fail. 2020; 13: e006977.
  4. 厚生労働省．高齢者の医薬品適正使用の指針．2019． https://www.mhlw.go.jp/content/11120000/000568037.pdf（2025年9月17日閲覧）
  5. Ando T, et al. Measurement of polydoctoring as a crucial component of fragmentation of care among patients with multimorbidity: Cross-sectional study in Japan. J Gen Fam Med. 2023; 24: 343–349.
  6. Green JL, et al. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother. 2007; 5: 31–39.
  7. Cullinan S, et al. A meta-synthesis of potentially inappropriate prescribing in older patients. Drugs Aging. 2014; 31: 631-638.
  8. Kojima T, et al. High risk of adverse drug reactions in elderly patients taking six or more drugs: analysis of inpatient database. Geriatr Gerontol Int. 2012; 12: 761–762.
  9. Pretorius RW, et al. Reducing the risk of adverse drug events in older adults. Am Fam Physician. 2013; 87: 331–336.
  10. Minamisawa M, et al. Association of Hyper-Polypharmacy With Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. Circ Heart Fail. 2021; 14: e008293.
  11. Hein C, et al. Impact of polypharmacy on occurrence of delirium in elderly emergency patients. J Am Med Dir Assoc. 2014; 15: 850.e11-15.
  12. Halli-Tierney AD, et al. Polypharmacy: Evaluating Risks and Deprescribing. Am Fam Physician. 2019; 100: 32–38.
  13. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. J Am Geriatr Soc. 2019; 67: 674–694.
  14. O’Mahony D, et al. STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med. 2023; 14: 625–632.
  15. 日本老年医学会，ほか．高齢者の安全な薬物療法ガイドライン2025：メジカルビュー社；2025．p1–172.
  16. Hanlon JT, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992; 45: 1045–1051.
  17. Scott IA, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Intern Med. 2015; 175: 827–834.
  18. Onyebeke C, et al. Polypharmacy and Guideline-Directed Medical Therapy Initiation Among Adults Hospitalized With Heart Failure. JACC Adv. 2024; 3: 101126.
  19. Fujihashi T, et al. Underuse of heart failure medications and poor long-term prognosis in chronic heart failure patients with polypharmacy - A report from the CHART-2 study. Int J Cardiol Heart Vasc. 2024; 50: 101345.
  20. Hadidi SE, et al. Potentially inappropriate prescriptions in heart failure with reduced ejection fraction: ESC position statement on heart failure with reduced ejection fraction-specific inappropriate prescribing. Eur Heart J Cardiovasc Pharmacother. 2022; 8: 187–210.
  21. Hill-Taylor B, et al. Effectiveness of the STOPP/START (Screening Tool of Older Persons' potentially inappropriate Prescriptions/Screening Tool to Alert doctors to the Right Treatment) criteria: systematic review and meta-analysis of randomized controlled studies. J Clin Pharm Ther. 2016; 41: 158–169.
  22. Verdoorn S, et al. Majority of drug-related problems identified during medication review are not associated with STOPP/START criteria. Eur J Clin Pharmacol. 2015; 71: 1255–1262.
  23. Potter K, et al. Deprescribing in Frail Older People: A Randomised Controlled Trial. PLoS One. 2016; 11: e0149984.
  24. Rankin A, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev. 2018; 9:CD008165.
  25. Haynes RB, et al. Clinical expertise in the era of evidence-based medicine and patient choice. Vox Sang. 2002; 83 Suppl 1: 383-386.
  26. Hoffmann TC, et al. The connection between evidence-based medicine and shared decision making. JAMA. 2014; 312: 1295–1296.

[8] ACP・心不全の緩和ケア

  1. 日本循環器学会．2021年JCS/JHFSガイドラインフォーカスアップデート版　急性・慢性心不全診療．日本内科学会雑誌．
  2. 日本循環器学会．急性・慢性心不全診療ガイドライン（2017年改訂版）
  3. 鳥崎哲平. 緩和ケア即戦力ノートーあなたにもできる、やさしい緩和ケア. 南江堂; 2023.
  4. 日本循環器学会/日本心不全学会合同ガイドライン．2021年改訂版　循環器疾患における緩和ケアについての提言． https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Anzai.pdf（2024年11月27日閲覧）
  5. Sobanski PZ, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res. 2020; 116: 12-27.
  6. Pattison M, et al. Improving Care Through the End of Life: launching a primary care clinic-based program. J Palliat Med. 2001; 4: 249-254.
  7. 厚生労働省．循環器疾患の患者に対する緩和ケア提供体制のあり方に関するワーキンググループ．循環器疾患の患者に対する緩和ケア提供体制のあり方について．2018. https://www.mhlw.go.jp/content/10905000/000468248.pdf（2024年11月27日閲覧）
  8. 日本緩和医療学会ガイドライン統括委員会（編）．がん患者の治療抵抗性の苦痛と鎮静に関する基本的な考え方の手引き2023年版． https://www.jspm.ne.jp/files/guideline/sedation_2023/sedation2023.pdf（2024年11月27日閲覧）
  9. Rutledge T, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006; 48: 1527-1537.
  10. 松田能宣，ほか. これからはじめる非がん患者の緩和ケア　第2版：じほう；2023．
  11. 会田薫子. 人生の物語りとadvance care planning．日本在宅救急医学会誌 2020；4： 31-37．
  12. 清水哲郎，ほか．臨床倫理の考え方と実践：東京大学出版会；2022．
  13. 厚生労働省．人生の最終段階における医療・ケアの決定プロセスに関するガイドライン　2018年改訂．https://www.mhlw.go.jp/file/04-Houdouhappyou-10802000-Iseikyoku-Shidouka/0000197701.pdf（2024年11月27日閲覧）
  14. 日本医師会．終末期医療　アドバンス・ケア・プランニング(ACP)から考える． https://www.med.or.jp/dl-med/teireikaiken/20180307_31.pdf（2025年9月17日閲覧）
  15. Desai AS, et al. Rehospitalization for heart failure: predict or prevent? Circulation. 2012; 126: 501-506.

[9]地域連携・ケア移行

  1. Desai AS, et al. Rehospitalization for heart failure: predict or prevent? Circulation. 2012; 126: 501-506.
  2. Madelaire C, et al. Burden and Causes of Hospital Admissions in Heart Failure During the Last Year of Life. JACC Heart Fail. 2019; 7: 561–570.
  3. Dharmarajan K, et al. Diagnoses and timing of 30-day readmissions after hospitalization for heart failure, acute myocardial infarction, or pneumonia. JAMA. 2013; 309: 355–363.
  4. Desai AS. The three-phase terrain of heart failure readmissions. Circ Heart Fail. 2012; 5: 398–400.
  5. Freund T, et al. Strategies for reducing potentially avoidable hospitalizations for ambulatory care-sensitive conditions. Ann Fam Med. 2013; 11: 363–370.
  6. Dharmarajan K, et al. Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study. BMJ. 2015; 350: h411.
  7. Phelan D, et al. Can we reduce preventable heart failure readmissions in patients enrolled in a Disease Management Programme? Ir J Med Sci. 2009; 178: 167–171.
  8. Hernandez AF, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010; 303: 1716–1722.
  9. https://www.ahrq.gov/research/findings/nhqrdr/chartbooks/carecoordination/measure1.html（2025年9月17日閲覧）
  10. https://www.ahrq.gov/ncepcr/care/coordination.html（2025年9月17日閲覧）
  11. Valentijn PP, et al. Understanding integrated care: a comprehensive conceptual framework based on the integrative functions of primary care. Int J Integr Care. 2013; 13: e010.
  12. Coleman EA, et al. Improving the quality of transitional care for persons with complex care needs. J Am Geriatr Soc. 2003; 51: 556–557.
  13. Glynn LG, et al. The prevalence of multimorbidity in primary care and its effect on health care utilization and cost. Fam Pract. 2011; 28: 516–523.
  14. Bodenheimer T. Coordinating care--a perilous journey through the health care system. N Engl J Med. 2008; 358: 1064–1071.
  15. Coleman EA, et al. Lost in transition: challenges and opportunities for improving the quality of transitional care. Ann Intern Med. 2004; 141: 533–536.
  16. Albert NM, et al. Transitions of care in heart failure: a scientific statement from the American Heart Association. Circ Heart Fail. 2015; 8: 384–409.
  17. Takeda A, et al. Clinical service organisation for heart failure. Cochrane Database Syst Rev. 2012; CD002752.
  18. Vedel I, et al. Transitional Care for Patients With Congestive Heart Failure: A Systematic Review and Meta-Analysis. Ann Fam Med. 2015; 13: 562–571.
  19. Writing Committee; Hollenberg SM, et al. 2024 ACC Expert Consensus Decision Pathway on Clinical Assessment, Management, and Trajectory of Patients Hospitalized With Heart Failure Focused Update: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2024; 84: 1241–1267.
  20. Girerd N, et al. Integrative Assessment of Congestion in Heart Failure Throughout the Patient Journey. JACC Heart Fail. 2018; 6: 273–285.
  21. Ambrosy AP, et al. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. Eur Heart J. 2013; 34: 835–843.
  22. Duarte K, et al. Prognostic Value of Estimated Plasma Volume in Heart Failure. JACC Heart Fail. 2015; 3: 886–893.
  23. Jovicic A, et al. Effects of self-management intervention on health outcomes of patients with heart failure: a systematic review of randomized controlled trials. BMC Cardiovasc Disord. 2006; 6: 43.
  24. Kinugasa Y, et al. Multidisciplinary intensive education in the hospital improves outcomes for hospitalized heart failure patients in a Japanese rural setting. BMC Health Serv Res. 2014; 14: 351.
  25. Lainscak M, et al. Nonpharmacologic measures and drug compliance in patients with heart failure: data from the EuroHeart Failure Survey. Am J Cardiol. 2007; 99: 31D–37D.
  26. Raat W, et al. Impact of primary care involvement and setting on multidisciplinary heart failure management: a systematic review and meta-analysis. ESC Heart Fail. 2021; 8: 802–818.
  27. Charteris EJ, et al. A nurse practitioner-led effort to reduce 30-day heart failure readmissions. J Am Assoc Nurse Pract. 2020; 32: 738–744.
  28. Rutledge T, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006; 48: 1527–1537.
  29. White-Williams C, et al.Addressing Social Determinants of Health in the Care of Patients With Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2020; 141: e841-e863.
  30. Jujo K, et al. Impact of Social Frailty in Hospitalized Elderly Patients With Heart Failure: A FRAGILE-HF Registry Subanalysis. J Am Heart Assoc. 2021; 10: e019954.
  31. https://plaza.umin.ac.jp/isobegroup/download_guide/（2025年9月17日閲覧）
  32. Kripalani S, et al. Deficits in communication and information transfer between hospital-based and primary care physicians: implications for patient safety and continuity of care. JAMA. 2007; 297: 831–841.
  33. Hoyer EH, et al. Association between days to complete inpatient discharge summaries with all-payer hospital readmissions in Maryland. J Hosp Med. 2016; 11: 393–400.
  34. Forster AJ, et al. The incidence and severity of adverse events affecting patients after discharge from the hospital. Ann Intern Med. 2003; 138: 161–167.
  35. Legault K, et al. Quality of discharge summaries prepared by first year internal medicine residents. BMC Med Educ. 2012; 12: 77.
  36. Al-Damluji MS, et al. Hospital variation in quality of discharge summaries for patients hospitalized with heart failure exacerbation. Circ Cardiovasc Qual Outcomes. 2015; 8: 77–86.
  37. Kinugasa Y, et al. Differences in Priorities for Heart Failure Management Between Cardiologists and General Practitioners in Japan. Circ J. 2021; 85: 1565-1574.
  38. Halasyamani L, et al. Transition of care for hospitalized elderly patients--development of a discharge checklist for hospitalists. J Hosp Med. 2006; 1: 354–360.
  39. British Journal of Cardiology. 2017;24(2):75-78.
  40. https://www.jhfs.or.jp/topics/shinhuzentecho.html（2025年9月17日閲覧）
  41. Hernandez AF, et al. Relationship between early physician follow-up and 30-day readmission among Medicare beneficiaries hospitalized for heart failure. JAMA. 2010; 303: 1716–1722.
  42. McAlister FA, et al. Early Follow-Up After a Heart Failure Exacerbation: The Importance of Continuity. Circ Heart Fail. 2016; 9: e003194.
  43. Bell CM, et al. Association of communication between hospital-based physicians and primary care providers with patient outcomes. J Gen Intern Med. 2009; 24: 381–386.
  44. Tsuchihashi-Makaya M, et al. Home-based disease management program to improve psychological status in patients with heart failure in Japan. Circ J. 2013; 77: 926–933.
  45. Coleman EA, et al. Lost in transition: challenges and opportunities for improving the quality of transitional care. Ann Intern Med. 2004; 141: 533–536.
  46. 文部科学省科研費事業　脆弱高齢者のケア移行時における診療情報伝達のための標準的フォーマット開発．医療者のための要介護高齢者における診療情報提供書作成ガイド．
  47. Mears P. New models of care for a local district general hospital. Future Hosp J. 2015; 2: 107–110.
  48. https://www.commonwealthfund.org/publications/case-study/2017/mar/caremore-improving-outcomes-and-controlling-health-care-spending（2025年9月17日閲覧）

[10]多職種連携

  1. 文部科学省．医学教育モデル・コア・カリキュラム　令和 4 年度改訂版.
  2. 草場鉄周（監）．総合診療・家庭医療のエッセンス第2版：カイ書林；2024．p154-178．

[11]医療経済

  1. 内閣府ホームページ．医療費適正化の観点からみた分析2019． https://www5.cao.go.jp/keizai-shimon/kaigi/special/reform/wg1/280331/shiryou1-2.pdf.（2025年9月17日閲覧）
  2. Drummond M et al. Methods for the Economic Evaluation of Health Care Programmes. 4th Edition: Oxford Medical Publications; 2015.
  3. Paulden M. Calculating and Interpreting ICERs and Net Benefit. Pharmacoeconomics. 2020; 38: 785–807.
  4. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022; 145: e876–e94.
  5. Gregory D, et al. Economic impact of beta blockade in heart failure. Am J Med. 2001; 110 Suppl 7A: 74S-80S.
  6. Caro JJ, et al. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial. J Card Fail. 2005; 11: 647-656.
  7. Delea TE, et al. Cost effectiveness of carvedilol for heart failure. Am J Cardiol. 1999; 83: 890-896.
  8. Banka G, et al. Incremental cost-effectiveness of guideline-directed medical therapies for heart failure. J Am Coll Cardiol. 2013; 61: 1440-1446.
  9. Glick HA, et al. Economic evaluation of the randomized aldactone evaluation study (RALES): treatment of patients with severe heart failure. Cardiovasc Drugs Ther. 2002; 16: 53-59.
  10. Zhang Z, et al. Cost effectiveness of eplerenone in patients with heart failure after acute myocardial infarction who were taking both ACE inhibitors and beta-blockers: subanalysis of the EPHESUS. Am J Cardiovasc Drugs. 2010; 10: 55-63.
  11. Weintraub WS, et al. Cost-effectiveness of eplerenone compared with placebo in patients with myocardial infarction complicated by left ventricular dysfunction and heart failure. Circulation. 2005; 111: 1106-1113.
  12. Glick H, et al. Costs and effects of enalapril therapy in patients with symptomatic heart failure: an economic analysis of the Studies of Left Ventricular Dysfunction (SOLVD) Treatment Trial. J Card Fail. 1995; 1: 371-380.
  13. Tsevat J, et al. Cost-effectiveness of captopril therapy after myocardial infarction. J Am Coll Cardiol. 1995; 26: 914-919.
  14. Reed SD, et al. Multinational economic evaluation of valsartan in patients with chronic heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J. 2004; 148: 122-128.
  15. McMurray JJV, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014; 371: 993-1004.
  16. Gaziano TA, et al. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction. JAMA Cardiol. 2016; 1: 666-672.
  17. King JB, et al. Cost-Effectiveness of Sacubitril-Valsartan Combination Therapy Compared With Enalapril for the Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2016; 4: 392-402.
  18. Sandhu AT, et al. Cost-Effectiveness of Sacubitril-Valsartan in Patients With Heart Failure With Reduced Ejection Fraction. Ann Intern Med. 2016; 165: 681-689.
  19. Gaziano TA, et al. Cost-effectiveness of Sacubitril-Valsartan in Hospitalized Patients Who Have Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2020; 5: 1236-1244.
  20. Parizo JT, et al. Cost-effectiveness of Dapagliflozin for Treatment of Patients With Heart Failure With Reduced Ejection Fraction. JAMA Cardiol. 2021; 6: 926-935.
  21. Isaza N, et al. Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction. JAMA Netw Open. 2021; 4: e2114501.
  22. Yan BW, et al. Cost-Effectiveness of Quadruple Therapy in Management of Heart Failure With Reduced Ejection Fraction in the United States. Circ Cardiovasc Qual Outcomes. 2023; 16: e009793.
  23. Dixit NM, et al. Cost-Effectiveness of Comprehensive Quadruple Therapy for Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2023; 11: 541-551.
  24. Kansal AR, et al. Cost-Effectiveness of Ivabradine for Heart Failure in the United States. J Am Heart Assoc. 2016; 5: e003221.
  25. Chew DS, et al. Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial. Circulation. 2023; 148: 1087-1098.
  26. Alsumali A, et al. Cost Effectiveness of Vericiguat for the Treatment of Chronic Heart Failure with Reduced Ejection Fraction Following a Worsening Heart Failure Event from a US Medicare Perspective. Pharmacoeconomics. 2021; 39: 1343-1354.
  27. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385: 1451-1461.
  28. Zhou J, et al. Cost-Effectiveness of Empagliflozin in Patients With Heart Failure and Preserved Ejection Fraction. Circ Cardiovasc Qual Outcomes. 2022; 15: e008638.
  29. Cohen LP, et al. Cost-effectiveness of Sodium-Glucose Cotransporter-2 Inhibitors for the Treatment of Heart Failure With Preserved Ejection Fraction. JAMA Cardiol. 2023; 8: 419-428.
  30. Shah KS, et al. Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. J Am Coll Cardiol. 2017; 70: 2476-2486.
  31. Kazi DS, et al. Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy. Circulation. 2020; 141: 1214-1224.
  32. Gillmore JD, et al. Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy. N Engl J Med. 2024; 390: 132-142.
  33. Marrouche NF, et al. Catheter Ablation for Atrial Fibrillation with Heart Failure. N Engl J Med. 2018; 378: 417-427.
  34. Chew DS, et al. Economic Evaluation of Catheter Ablation of Atrial Fibrillation in Patients with Heart Failure With Reduced Ejection Fraction. Circ Cardiovasc Qual Outcomes. 2020; 13: e007094.
  35. Chew DS, et al. Cost-Effectiveness of Coronary Artery Bypass Surgery Versus Medicine in Ischemic Cardiomyopathy: The STICH Randomized Clinical Trial. Circulation. 2022; 145: 819-828.
  36. Perera D, et al. Percutaneous Revascularization for Ischemic Left Ventricular Dysfunction. N Engl J Med. 2022; 387: 1351-1360.
  37. Zwanziger J, et al. The cost effectiveness of implantable cardioverter-defibrillators: results from the Multicenter Automatic Defibrillator Implantation Trial (MADIT)-II. J Am Coll Cardiol. 2006; 47: 2310-2318.
  38. Mark DB, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006; 114: 135-142.
  39. Mushlin AI, et al. The cost-effectiveness of automatic implantable cardiac defibrillators: results from MADIT. Multicenter Automatic Defibrillator Implantation Trial. Circulation. 1998; 97: 2129-2135.
  40. Noyes K, et al. Cost-effectiveness of cardiac resynchronization therapy in the MADIT-CRT trial. J Cardiovasc Electrophysiol. 2013; 24: 66-74.
  41. Gold MR, et al. Economic Value and Cost-Effectiveness of Cardiac Resynchronization Therapy Among Patients With Mild Heart Failure: Projections From the REVERSE Long-Term Follow-Up. JACC Heart Fail. 2017; 5: 204-212.
  42. Feldman AM, et al. Cost effectiveness of cardiac resynchronization therapy in the Comparison of Medical Therapy, Pacing, and Defibrillation in Heart Failure (COMPANION) trial. J Am Coll Cardiol. 2005; 46: 2311-2321.
  43. Tam DY, et al. The cost-effectiveness of transcatheter aortic valve replacement in low surgical risk patients with severe aortic stenosis. Eur Heart J Qual Care Clin Outcomes. 2021; 7: 556-563.
  44. Baron SJ, et al. Cost-Effectiveness of Transcatheter Mitral Valve Repair Versus Medical Therapy in Patients With Heart Failure and Secondary Mitral Regurgitation: Results From the COAPT Trial. Circulation. 2019; 140: 1881-1891.
  45. Rogers JG, et al. Cost-effectiveness analysis of continuous-flow left ventricular assist devices as destination therapy. Circ Heart Fail. 2012; 5: 10-16.
  46. Long EF, et al. Comparative survival and cost-effectiveness of advanced therapies for end-stage heart failure. Circ Heart Fail. 2014; 7: 470-478.
  47. Shreibati JB, et al. Cost-Effectiveness of Left Ventricular Assist Devices in Ambulatory Patients With Advanced Heart Failure. JACC Heart Fail. 2017; 5: 110-119.
  48. Mahr C, et al. Cost-Effectiveness of Thoracotomy Approach for the Implantation of a Centrifugal Left Ventricular Assist Device. ASAIO J. 2020; 66: 855-861.
  49. Silvestry SC, et al. Cost-Effectiveness of a Small Intrapericardial Centrifugal Left Ventricular Assist Device. ASAIO J. 2020; 66: 862-870.
  50. Khush KK, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult heart transplantation report - 2019; focus theme: Donor and recipient size match. J Heart Lung Transplant. 2019; 38: 1056-1066.
  51. Van Spall HGC, et al. Comparative effectiveness of transitional care services in patients discharged from the hospital with heart failure: a systematic review and network meta-analysis. Eur J Heart Fail. 2017; 19: 1427-1443.
  52. Blum MR, et al. Cost-Effectiveness of Transitional Care Services After Hospitalization With Heart Failure. Ann Intern Med. 2020; 172: 248-257.
  53. Rao BR, et al. Impact of Financial Considerations on Willingness to Take Sacubitril/Valsartan for Heart Failure. J Am Heart Assoc. 2022; 11: e023789.

[12] 心不全のマルチモビディティ

  1. 大浦誠．週間医学界新聞　ケースで学ぶマルチモビディティ．医学書院．
  2. Tromp J, et al. Multimorbidity in patients with heart failure from 11 Asian regions: A prospective cohort study using the ASIAN-HF registry. PLoS Med. 2018; 15: e1002541.
  3. Aoki T, et al. Multimorbidity patterns in relation to polypharmacy and dosage frequency: a nationwide, cross-sectional study in a Japanese population. Sci Rep. 2018; 8: 3806.
  4. Mercer S, et al. ABC of Multimorbidity(ABC Series). BMJ Books WILEY Blackwell; 2014.

Part2　心不全進展ステージ　パターン別寄り添い方

[1] 心不全の病みの軌跡　ステージA（生活習慣病持ち）

  1. Heidenreich PA, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation 2022; 145: e895-e1032.
  2. Kostis JB, et al. Prevention of heart failure by antihypertensive drug treatment in older persons with isolated systolic hypertension. SHEP Cooperative Research Group. JAMA. 1997; 278: 212-216.
  3. 日本高血圧学会高血圧治療ガイドライン作成委員会．高血圧治療ガイドライン2019：ライフサイエンス出版；2019．
  4. McEvoy JW, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024; 45: 3912-4018.
  5. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021; 42: 2439–2454.
  6. Levy D, et al. The progression from hypertension to congestive heart failure. JAMA. 1996; 275: 1557-1562.
  7. Wilhelmsen L, et al. Heart failure in the general population of men--morbidity, risk factors and prognosis. J Intern Med. 2001; 249: 253-261.
  8. Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018; 71: 1269-1324.
  9. Nagappa M, et al. Validation of the STOP-Bang Questionnaire as a Screening Tool for Obstructive Sleep Apnea among Different Populations: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10: e 0143697.
  10. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991; 14: 540-545.
  11. Choy KW, et al. Primary aldosteronism. BMJ. 2022; 377: e065250.
  12. 日本内分泌学会（監），日本内分泌学会原発性アルドステロン症診療ガイドライン策定と診断水準向上委員会（編）．原発性アルドステロン症診療ガイドライン2021；2021．
  13. 吉田雄一，ほか．原発性アルドステロン症の診療アップデート．日本内科学会雑誌 2018；　107：667-673．
  14. Yancy CW, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013; 62: e147-239.
  15. Tucker KL, et al. Self-monitoring of blood pressure in hypertension: A systematic review and individual patient data meta-analysis. PLoS Med. 2017; 14: e1002389.
  16. Bradley CK, et al. Use of Different Blood Pressure Thresholds to Reduce the Number of Home Blood Pressure Monitoring Days Needed for Detecting Hypertension. Hypertension. 2023; 80: 2169-2177.
  17. Vodnala D, et al. Secondary causes of dyslipidemia. Am J Cardiol. 2012; 110: 823-825.
  18. 日本動脈硬化学会．動脈硬化性疾患予防ガイドライン2022年版：日本動脈硬化学会；2022．
  19. Lind M, et al. Glycaemic control and incidence of heart failure in 20,985 patients with type 1 diabetes: an observational study. Lancet. 2011; 378: 140-146.
  20. Coyle JD, et al. The renal protective effects of angiotensin II receptor blockers in type 2 diabetes mellitus. Ann Pharmacother. 2004; 38: 1731-1738.
  21. Berl T, et al. Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med. 2003; 138: 542-549.
  22. Brenner BM, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345: 861-869.
  23. Yusuf S, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000; 342: 145-153.
  24. Zinman B, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373: 2117-2128.
  25. Neal B, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377: 644-657.
  26. Stewart M et al. Patient-Centered Medicine: Transforming the Clinical Method. 3rd edition: CRC Press; 2014.
  27. 亀田メディカルセンター．予防医療の薦め2024． https://www.kameda.com/pr/health/index.html（2025年7月29日閲覧）

[2] 心不全の病みの軌跡　ステージB（心房細動）

  1. Inoue H, et al. Prevalence of atrial fibrillation in the general population of Japan: an analysis based on periodic health examination. Int J Cardiol. 2009; 137: 102-107.
  2. Van Gelder IC, et al. 2024 ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2024; 45: 3314-3414.
  3. Pathak RK, et al. Aggressive risk factor reduction study for atrial fibrillation and implications for the outcome of ablation: the ARREST-AF cohort study. J Am Coll Cardiol. 2014; 64: 2222-2231.
  4. 日本循環器学会 /日本不整脈心電学会合同ガイドライン．不整脈非薬物治療ガイドライン（2020年改訂版）．
  5. Camm AJ, et al. Mortality in Patients With Atrial Fibrillation Receiving Nonrecommended Doses of Direct Oral Anticoagulants. J Am Coll Cardiol. 2020; 76: 1425-1436.
  6. Wyse DG, A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002; 347: 1825-1833.
  7. Kirchhof P, et al. Early Rhythm-Control Therapy in Patients with Atrial Fibrillation. N Engl J Med. 2020; 383: 1305-1316.
  8. Andrade JG, et al. Progression of Atrial Fibrillation after Cryoablation or Drug Therapy. N Engl J Med. 2023; 388: 105-116.
  9. Reddy VY, et al. Pulsed Field Ablation for Pulmonary Vein Isolation in Atrial Fibrillation. J Am Coll Cardiol. 2019; 74: 315-326.
  10. Kalman JM, et al. Impact of early vs. delayed atrial fibrillation catheter ablation on atrial arrhythmia recurrences. Eur Heart J. 2023; 44: 2447-2454.
  11. Karnik AA, et al. Epidemiology of Atrial Fibrillation and Heart Failure: A Growing and Important Problem. Cardiol Clin. 2019; 37: 119-129.
  12. Reddy YNV, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018; 138: 861-870.
  13. Reddy YNV, et al. Screening for Unrecognized HFpEF in Atrial Fibrillation and for Unrecognized Atrial Fibrillation in HFpEF. JACC Heart Fail. 2024; 12: 990-998.
  14. Sugumar H, et al. A prospective STudy using invAsive haemodynamic measurements foLLowing catheter ablation for AF and early HFpEF: STALL AF-HFpEF. Eur J Heart Fail. 2021; 23: 785-796.
  15. An Y, et al. Causes of death in Japanese patients with atrial fibrillation: The Fushimi Atrial Fibrillation Registry. Eur Heart J Qual Care Clin Outcomes. 2019; 5: 35-42.
  16. Ogawa H, et al. Progression From Paroxysmal to Sustained Atrial Fibrillation Is Associated With Increased Adverse Events. Stroke. 2018; 49: 2301-2308.
  17. Hamatani Y, et al. Utility of left ventricular ejection fraction in atrial fibrillation patients without pre-existing heart failure. ESC Heart Fail. 2023; 10: 3091-3101.
  18. Hamatani Y, et al. Association of left atrial enlargement with heart failure events in non-valvular atrial fibrillation patients with preserved left ventricular ejection fraction. Eur Heart J Open. 2024; 4: oeae015.
  19. Hamatani Y, et al. Prognostic significance of natriuretic peptide levels in atrial fibrillation without heart failure. Heart. 2021; 107: 705-712.
  20. Rillig A, et al. Early Rhythm Control Therapy in Patients With Atrial Fibrillation and Heart Failure. Circulation. 2021; 144: 845-858.

[3] 心不全の病みの軌跡　ステージB（心筋梗塞）

  1. 日本循環器学会．急性冠症候群ガイドライン(2018年改訂版)． https://www.j-circ.or.jp/cms/wp-content/uploads/2018/11/JCS2018_kimura.pdf（2025年8月1日閲覧）
  2. Bainey KR, et al. Complete vs Culprit-Lesion-Only Revascularization for ST-Segment Elevation Myocardial Infarction: A Systematic Review and Meta-analysis. JAMA Cardiol. 2020; 5: 881–888.
  3. Gershlick AH, et al. Randomized trial of complete versus lesion-only revascularization in patients undergoing primary percutaneous coronary intervention for STEMI and multivessel disease: the CvLPRIT trial. J Am Coll Cardiol. 2015; 65: 963-972.
  4. 日本循環器学会．2020年JCSガイドラインフォーカスアップデート版冠動脈疾患患者における抗血栓療法． https://www.j-circ.or.jp/cms/wp-content/uploads/2020/04/JCS2020_Kimura_Nakamura.pdf（2025年8月1日閲覧）
  5. Oesterle A, et al. Pleiotropic Effects of Statins on the Cardiovascular System. Circ Res. 2017; 120: 229-243.
  6. Byrne RA, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J. 2023; 44: 3720-3826.
  7. 日本循環器学会/日本心臓リハビリテーション学会合同ガイドライン．2021年改訂版心血管疾患におけるリハビリテーションに関するガイドライン. https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Makita.pdf（2025年8月1日閲覧）
  8. Kamiya K, et al. Nationwide Survey of Multidisciplinary Care and Cardiac Rehabilitation for Patients With Heart Failure in Japan - An Analysis of the AMED-CHF Study. Circ J. 2019; 83: 1546-1552.
  9. Jenča D, et al. Heart failure after myocardial infarction: incidence and predictors. ESC Heart Fail. 2021; 8: 222 -237.
  10. Desta L, et al. Risk and predictors of readmission for heart failure following a myocardial infarction between 2004 and 2013: A Swedish nationwide observational study. Int J Cardiol. 2017; 248: 221–226.
  11. Frantz S, et al. Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies. Eur Heart J. 2022; 43: 2549–2561.
  12. Butler J, et al. Incident heart failure and recurrent coronary events following acute myocardial infarction. Eur Heart J. 2025; 46: 1540–1550.
  13. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group. Circulation. 1998; 97: 2202-2212.
  14. Pfeffer MA, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med. 2003; 349: 1893-1906.
  15. Freemantle N, et al. beta Blockade after myocardial infarction: systematic review and meta regression analysis. BMJ. 1999; 318: 1730–1737.
  16. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001; 357: 1385 -1390.
  17. Watanabe H, et al. Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. PLoS One. 2018; 13: e0199347.
  18. Pitt B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003; 348: 1309-1321.
  19. Jolly SS, et al. Routine Spironolactone in Acute Myocardial Infarction. N Engl J Med. 2025; 392: 643-652.
  20. Pfeffer MA, et al. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction. N Engl J Med. 2021; 385: 1845-1855.
  21. Butler J, et al. Empagliflozin after Acute Myocardial Infarction. N Engl J Med. 2024; 390: 1455-1466.
  22. Hernandez AF, et al. Effect of Empagliflozin on Heart Failure Outcomes After Acute Myocardial Infarction: Insights From the EMPACT-MI Trial. Circulation. 2024; 149: 1627-1638.

[4] 心不全　ステージC（初発の心不全HFrEF）

  1. Shiba N, et al. Trend of westernization of etiology and clinical characteristics of heart failure patients in Japan--first report from the CHART-2 study. Circ J. 2011; 75: 823-833.
  2. 日本循環器学会/日本心不全学会合同ガイドライン．急性･慢性心不全診療ガイドライン（2017年改訂版）． https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000202651.pdf（2025年9月17日閲覧）
  3. Chen G, et al. Study on the Application Effect of Nursing Intervention Based on the Transtheoretical Model in the Rehabilitation Treatment of Patients with Chronic Heart Failure. Altern Ther Health Med. 2024; 30: 375-383.
  4. Raihan N, et al. Stages of Change Theory. StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.
  5. 日本循環器学会/日本心不全学会合同ガイドライン．2021年改訂版　循環器疾患における緩和ケアについての提言． https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Anzai.pdf（2025年9月17日閲覧）
  6. Celano CM, et al. Depression and Anxiety in Heart Failure: A Review, Harv Rev Psychiatry. 2018; 26:175-184.
  7. Rutledge T, et al. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol. 2006; 48: 1527-1537.
  8. Go AS, et al. Heart disease and stroke statistics--2014 update: a report from the American Heart Association. Circulation. 2014; 129: e28-e292.

[5] 心不全の病みの軌跡　ステージC（HFpEF 総合診療医がみる心不全）

  1. Cannata A, et al. Heart Failure with Preserved Ejection Fraction. N Engl J Med. 2025; 392: 173–184.
  2. Ho JE, et al. Predicting Heart Failure With Preserved and Reduced Ejection Fraction: The International Collaboration on Heart Failure Subtypes. Circ Heart Fail. 2016; 9: e003116.
  3. Reddy YNV, et al. A Simple, Evidence-Based Approach to Help Guide Diagnosis of Heart Failure With Preserved Ejection Fraction. Circulation. 2018; 138: 861–870.
  4. Kitzman DW, et al. Effect of Caloric Restriction or Aerobic Exercise Training on Peak Oxygen Consumption and Quality of Life in Obese Older Patients With Heart Failure With Preserved Ejection Fraction: A Randomized Clinical Trial. JAMA. 2016; 315: 36–46.
  5. Solomon SD, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2024; 391: 1475–1485.
  6. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385: 1451–1461.
  7. Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387: 1089–1098.
  8. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2023; 389: 1069–1084.
  9. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025; 392: 427-437.
  10. Stuck AE, et al. Comprehensive geriatric assessment: a meta-analysis of controlled trials. Lancet. 1993; 342: 1032–1036.
  11. Halasyamani L, et al. Transition of care for hospitalized elderly patients--development of a discharge checklist for hospitalists. J Hosp Med. 2006; 1: 354-360.
  12. Gaddey HL, et al. Unintentional Weight Loss in Older Adults. Am Fam Physician. 2021; 104: 34–40.
  13. Haynes RB, et al. Can simple clinical measurements detect patient noncompliance? Hypertension. 1980; 2: 757–764.

[6] 心不全の病みの軌跡　ステージD（HFrEF）

  1. 日本循環器学会/日本心不全学会合同ガイドライン．2025年改訂版　心不全診療ガイドライン． https://www.j-circ.or.jp/cms/wp-content/uploads/2025/03/JCS2025_Kato.pdf（2025年4月10日閲覧）
  2. 日本循環器学会/日本心不全学会合同ガイドライン．急性･慢性心不全診療ガイドライン（2017年改訂版）． https://www.mhlw.go.jp/file/05-Shingikai-10901000-Kenkoukyoku-Soumuka/0000202651.pdf（2025年9月17日閲覧）
  3. Kinugawa K, et al. Consensus Report on Destination Therapy in Japan - From the DT Committee of the Council for Clinical Use of Ventricular Assist Device Related Academic Societies. Circ J. 2021; 85: 1906-1917.
  4. 日本心不全学会・日本在宅医療連合学会．重症心不全患者への在宅静注強心薬持続投与指針第1版． https://www.jahcm.org/assets/images/pdf/statement20240326.pdf （2025年9月17日閲覧）
  5. Levy WC, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006; 113: 1424-1433.
  6. Shiraishi Y, et al. Validation and Recalibration of Seattle Heart Failure Model in Japanese Acute Heart Failure Patients. J Card Fail. 2019; 25: 561-567.
  7. Gupta A, et al. The Surprise Question and clinician-predicted prognosis: systematic review and meta-analysis. BMJ Support Palliat Care. 2024; 15: 12-35.
  8. 日本循環器学会/日本心不全学会合同ガイドライン．2021年改訂版　循環器疾患における緩和ケアについての提言． https://www.j-circ.or.jp/cms/wp-content/uploads/2021/03/JCS2021_Anzai.pdf（2025年5月4日閲覧）
  9. HEPT(心不全緩和ケアトレーニングコース)．https://hept.jp/
  10. Bauersachs J. Heart failure drug treatment: the fantastic four. Eur Heart J. 2021; 42: 681-683.
  11. Tromp J, et al. A Systematic Review and Network Meta-Analysis of Pharmacological Treatment of Heart Failure With Reduced Ejection Fraction. JACC Heart Fail. 2022; 10; 73-84.
  12. 大坂 巌，ほか．わが国におけるWHO緩和ケア定義の定訳─デルファイ法を用いた緩和ケア関連18団体による共同作成─． Palliat Care Res　2019；14：61-66．
  13. Sobanski PZ, et al. Palliative care for people living with heart failure: European Association for Palliative Care Task Force expert position statement. Cardiovasc Res. 2020; 116: 12-27.
  14. Sakurai H, et al. Validation of the Integrated Palliative care Outcome Scale (IPOS) - Japanese Version. Jpn J Clin Oncol. 2019; 49: 257-262.
  15. Hamatani Y, et al. Comprehensive symptom assessment using Integrated Palliative care Outcome Scale in hospitalized heart failure patients. ESC Heart Fail. 2022; 9: 1963-1975.
  16. Miyashita J, et al. Culturally Adapted Consensus Definition and Action Guideline: Japan's Advance Care Planning. J Pain Symptom Manage. 2022; 64: 602-613.
  17. 日本緩和医療学会ガイドライン統括委員会（編）．がん患者の治療抵抗性の苦痛と鎮静に関する基本的な考え方の手引き2023年版． https://www.jspm.ne.jp/files/guideline/sedation_2023/sedation2023.pdf（2025年9月17日閲覧）
  18. Back AL, et al. Approaching difficult communication tasks in oncology. CA Cancer J Clin. 2005; 55: 164-177.

[7] 心不全　ステージD（HFpEF患者への寄り添い方）

  1. Yaku H, et al. Demographics, Management, and In-Hospital Outcome of Hospitalized Acute Heart Failure Syndrome Patients in Contemporary Real Clinical Practice in Japan - Observations From the Prospective, Multicenter Kyoto Congestive Heart Failure (KCHF) Registry. Circ J. 2018; 82: 2811-2819.
  2. Martin CM, et al. General practice--chaos, complexity and innovation. Med J Aust. 2005; 183: 106-109.
  3. Buckman R. Breaking bad news: why is it still so difficult? Br Med J (Clin Res Ed). 1984; 288: 1597-1599.
  4. Weeks JC, et al. Patients' expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012; 367:1616-1625.
  5. Johnson S, et al. Advance care planning for cancer patients: a systematic review of perceptions and experiences of patients, families, and healthcare providers. Psychooncology. 2016; 25: 362-386.
  6. Back AL, et al. Approaching difficult communication tasks in oncology. CA Cancer J Clin. 2005; 55: 164-177.

COLUMN

COLUMN 01　過負荷を避け運動の楽しみ、喜びを残す

  1. O’Connor CM, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA. 2009; 301: 1439-1450.

COLUMN 02　心不全に対する薬剤効果を多面的に考察するための視座

  1. Anker SD, et al. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021; 385: 1451-1461.
  2. Solomon SD, et al. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. N Engl J Med. 2022; 387: 1089-1098.

COLUMN 04　心不全のケアに健康の社会的決定要因（SDH）の視点を

  1. Aryee EK, et al. Heart Failure and Obesity: The Latest Pandemic. Prog Cardiovasc Dis. 2023; 78: 43-48.
  2. Isobe M. The Heart Failure "Pandemic" in Japan: Reconstruction of Health Care System in the Highly Aged Society. JMA J. 2019; 2: 103-112.
  3. Enard KR, et al. Influence of Social Determinants of Health on Heart Failure Outcomes: A Systematic Review. J Am Heart Assoc. 2023; 12: e026590.
  4. Matsushita M, et al. Social determinants are crucial factors in the long-term prognosis of severely decompensated acute heart failure in patients over 75 years of age. J Cardiol. 2018; 72: 140-148.
  5. Saito H, et al. Social isolation is associated with 90-day rehospitalization due to heart failure. Eur J Cardiovasc Nurs. 2019; 18: 16-20.
  6. Wong FK, et al. Effects of a health-social partnership transitional program on hospital readmission: a randomized controlled trial. Soc Sci Med. 2011; 73: 960-969.

COLUMN 06　妊娠、分娩で循環動態はどう変わる？　心疾患合併妊娠に対する管理戦略

  1. 日本循環器学会/日本産科婦人科学会合同ガイドライン．心疾患患者の妊娠・出産の適応，管理に関するガイドライン（2018 年改訂版） https://www.j-circ.or.jp/cms/wp-content/uploads/2018/06/JCS2018_akagi_ikeda.pdf （2025年9月17日閲覧）
  2. Zagrosek VR, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J. 2018; 39: 3165-3241.

COLUMN 07　ストレスが引き金に？　たこつぼ症候群、見逃し注意！

  1. Sato H, et al. Tako-tsubo-like left ventricular dysfunction due to multivessel coronary spasm. In: Kodama K, et al, editors. Clinical aspect of myocardial injury: From ischemia to heart failure, Kagakuhyoronsha Publishing Co; 1990. p56-64.
  2. Lyon AR, et al. Current state of knowledge on Takotsubo syndrome: a Position Statement from the Taskforce on Takotsubo Syndrome of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2016; 18: 8-27.
  3. Templin C, et al. Clinical Features and Outcomes of Takotsubo (Stress) Cardiomyopathy. N Engl J Med. 2015; 373: 929-938.
  4. Schweiger V, et al. Temporal Trends in Takotsubo Syndrome: Results From the International Takotsubo Registry. J Am Coll Cardiol. 2024; 84: 1178-1189.
  5. Kato K, et al. Takotsubo syndrome: aetiology, presentation and treatment. Heart. 2017; 103: 1461-1469.
  6. Ghadri JR, et al. Happy heart syndrome: role of positive emotional stress in takotsubo syndrome. Eur Heart J. 2016; 37: 2823-2829.
  7. Kato K, et al. Cardiogenic shock in takotsubo syndrome: etiology and treatment. Cardiovasc Interv Ther. 2024; 39: 421-427.
  8. Ghadri JR, et al. International Expert Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria, and Pathophysiology. Eur Heart J. 2018; 39: 2032-2046.
  9. Ghadri JR, et al. International Expert Consensus Document on Takotsubo Syndrome (Part II): Diagnostic Workup, Outcome, and Management. Eur Heart J. 2018; 39: 2047-2062.
  10. Kato K, et al. Takotsubo Recurrence: Morphological Types and Triggers and Identification of Risk Factors. J Am Coll Cardiol. 2019; 73: 982-984.

COLUMN 08　心不全患者のCKM（保存的腎臓療法）と透析

  1. 新田孝作，ほか．わが国の慢性透析療法の現状．日本透析医学会雑誌　2020；53：579-632．
  2. 水口 潤．高齢化社会における腹膜透析普及への課題．日本透析医会雑誌　2023；Vol. 38 No. 1：14-21．
  3. 森 建文．心不全を合併した腹膜透析患者に対する学会主導プロジェクトチーム．臨床透析　2024：vol.40 no.5：541-544．
  4. 大武陽一. 慢性腎臓病（CKD）. 非がん患者の緩和ケア第２版. じほう；2023： 90-114．
  5. 日本緩和医療学会ガイドライン統括委員会．がん疼痛の薬物療法に関するガイドライン　2020年版：金原出；p53-66．
  6. 西村勝治．サイコネフロロジー ―今日的課題と展望―．日本透析医会雑誌 2019；vol.34 No.3：p476-483．

テンプレートファイル

退院診療情報提供書・退院後初診時チェックリストのテンプレートをダウンロードできます。

書誌情報

書名
病みの軌跡を意識した　患者に寄り添う心不全診療―薬物療法・非薬物療法から緩和療法・ACPまで―
編著者
齋藤秀輝、官澤洋平
判型等
四六判　432頁
ISBN
978-4-7653-2072-6
定価
本体価格5,400円＋税

書誌頁に戻る